Drug Index

Methsuximide

 
print

Mechanism :

Increases the seizure threshold and suppresses paroxysmal spike-and-wave pattern in absence seizures; depresses nerve transmission in the motor cortex.


Indication :

• Refractory Absence seizures


Contraindications :

History of hypersensitivity to succinimides.


Dosing :

>12 years: Initial: 300 mg/day PO. May increase by 300 mg/week; not to exceed 1.2 g/day in divided doses.


Adverse Effect :

Aggressiveness, ataxia, confusion, depression, dizziness, drowsiness, hallucinations (auditory), headache, hypochondriacal behaviour, insomnia, irritability, Pruritus, rash, Stevens-Johnson syndrome, urticarial, Eosinophilia, leukopenia, monocytosis, Blurred vision, periorbital edema, photophobia, hiccups, systemic lupus erythematosus.


Interaction :

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.
CYP2C19 Inducers: May increase the metabolism of CYP2C19 Substrates.
CYP2C19 Inhibitors: May decrease the metabolism of CYP2C19 Substrates.
Mefloquine: May diminish the therapeutic effect of Anticonvulsants.
Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.


07/18/2019 01:43:52 Methsuximide
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0